(Q38945299)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

0 references

1 reference

title

Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

0 references

Fernando Queiroz Cunha

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

José M Mota

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Ronaldo A Ribeiro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Carlos W S Wanderley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Deysi V T Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Caio A V G Leite

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Marcellus H L P Souza

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Roberto C P Lima-Júnior

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

publication date

2 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

881-893

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27590709%20AND%20SRC:MED&resulttype=core&format=json

Updated clinical practice guidelines for the prevention and treatment of mucositis

22 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Oral and intestinal mucositis — causes and possible treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Current perspectives on camptothecins in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Lessons learned from the irinotecan metabolic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Guidance on the management of diarrhoea during cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Molecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Intestinal microflora and digestive toxicity of irinotecan in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Downregulation of topoisomerase I in differentiating human intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

New dimension in therapeutic targeting of BCL-2 family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Role of p53 in irinotecan-induced intestinal cell death and mucosal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Caspase functions in cell death and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Toll-like receptors in inflammation, infection and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

DAMPs, PAMPs and alarmins: all we need to know about danger

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

21 January 2018

TLR signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Upregulation of TLRs and IL-6 as a marker in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

TLR signaling modulates side effects of anticancer therapy in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Management of oral and gastrointestinal mucositis: ESMO clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Prevention of irinotecan plus5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Understanding and modulating mammalian-microbial communication for improved human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Gut microbiota disturbance during antibiotic therapy: a multi-omic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y

Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3139-Y